This project will focus on the development and production of the clinical reagents necessary to carry out human trials with three separate radiolabeled monoclonal antibodies in the setting of bone marrow transplantation. Bone marrow transplantation is one of the most effective ways of dealing with a variety of leukemias and lymphomas, however, in certain cases, the disease of the patient is not irradicated by the pre- transplant therapy. In general, patients are treated with high dose chemotherapy as well as fractionated total body radiation therapy as part of their conditioning regimen prior to transplant. The radiolabeled monoclonal antibodies developed in this project will be used for supplementaing the fractionated total body radiation therapy in an effort to improve long term disease free intervals. The project will develop three different monoclonal antibodies. One directed against the antigen CD33, one directed against the antigen CD45, and one directed against the antigen CD20. CD33 is a common antigen found on the vast majority of cells in acute myelogenous leukemia. The radiolabeled antibody will therefore be used as an adjunct to the conditioning regimen for patients with acute myelogenous leukemia undergoing bone marrow transplantation, as well as other patients with VCD33 positive disease including those patients with CML and myuelodysplastic disorders. The second antibody being developed is an anti-CD45 antibody. CD45 is found on almost all hematopoietic cells and therefore represents a target for clinical reagents for not only patient with acute myelogenous leukemia, but patients with lymphocytic leukemias as well. The third antibody developed is an anti-CD20 antibogy which recognized a common antigen found on normal and malignant lymphocytes of the B-cell lineage. Most lymphomas are of the B-cell origin and express CD20 and will serve as the target patient population for this radiolabeled antibody. The radiolabeling effort will focus on using the heavy metal isotope Yttrium-90 as a means of delivering significant doses of irradiation to involved tumor sites and bone marrow. Yttrium-90 may be preferred over iodine because of its higher specific activity, longer range of beta emission, absence of high energy gamma, and bone seeking capabilities. The anti-CD20 antibody will also be the focus of molecular engineering in order to improve it's biodistribution and therefore it's clinical utility. A bi-functional antibody molecular construct with a molecular weight of approximately 80,000 will be the initial construct engineered. Further molecular constructs will include antibodies for subsequent site specific modification and fusion proteins. The final aspect will be to apply better chelating agents for holding the radiometal attached to the monoclonal antibody. The reagents will focus on compounds of the macrocyclic class exemplified by the molecular DOTA. Further modification of this DOTA chelate will be evaluated as potential reagents for clinical utility in the treatment of the leukemias and lymphomas covered under this study.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA030206-17
Application #
6269142
Study Section
Project Start
1998-09-18
Project End
1999-01-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
17
Fiscal Year
1998
Total Cost
Indirect Cost
Name
City of Hope National Medical Center
Department
Type
DUNS #
City
Duarte
State
CA
Country
United States
Zip Code
91010
Limaye, Ajit P; La Rosa, Corinna; Longmate, Jeff et al. (2016) Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. Transplantation 100:210-6
Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68
Wang, Xiuli; Wong, ChingLam W; Urak, Ryan et al. (2015) CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clin Cancer Res 21:2993-3002
Mardiros, Armen; Forman, Stephen J; Budde, Lihua E (2015) T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol 22:484-8
Caruso, Hillary G; Hurton, Lenka V; Najjar, Amer et al. (2015) Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res 75:3505-18
Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33
Wussow, Felix; Chiuppesi, Flavia; Martinez, Joy et al. (2014) Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog 10:e1004524
Rushworth, David; Jena, Bipulendu; Olivares, Simon et al. (2014) Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity. J Immunother 37:204-13
Jena, Bipulendu; Moyes, Judy S; Huls, Helen et al. (2014) Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep 9:50-6
Singh, Harjeet; Huls, Helen; Kebriaei, Partow et al. (2014) A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 257:181-90

Showing the most recent 10 out of 364 publications